Molecular and cellular signatures of human vaccine adjuvants

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 30, 2008, Pages 10501-10506

  Mosca, F ^a   Tritto, E ^a   Muzzi, A ^a   Monaci, E ^a   Bagnoli, F ^a   Iavarone, C ^a   O'Hagan, D ^a   Rappuoli, R ^a   De Gregorio, E ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

Alum; CpG; Innate immunity; MF59; Microarray; Oligonucleotide

Indexed keywords

ALUMINUM POTASSIUM SULFATE; CD11B ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; CYTOKINE RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; PENTRAXIN 3; TRANSCRIPTION FACTOR JUNB;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE TARGETING; HUMAN; IMMUNOFLUORESCENCE; INNATE IMMUNITY; LEUKOCYTE MIGRATION; MICROARRAY ANALYSIS; MUSCLE CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; SKELETAL MUSCLE;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIGENS, CD11B; CPG ISLANDS; CYTOKINES; GENE EXPRESSION REGULATION; GENES, MHC CLASS II; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INFLUENZA VACCINES; MICE; MUSCLE, SKELETAL; POLYSORBATES; QUADRICEPS MUSCLE; SQUALENE;

EID: 48749120743     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0804699105     Document Type: Article

References (29)

1. Fraser CK, Diener KR, Brown MP, Hayball JD (2007) Improving vaccines by incorporating immunological coadjuvants. Exp Rev Vaccines 6:559-578.
2. Guy B (2007) The perfect mix: Recent progress in adjuvant research. Nat Rev Microbiol 5:505-517.
3. Pashine A, Valiante NM, Ulmer JB (2005) Targeting the innate immune response with improved vaccine adjuvants. Nat Med 11:S63-68.
4. Gavin AL, et al. (2006) Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 314:1936-1938.
5. Nemazee D, Gavin A, Hoebe K, Beutler B (2006) Immunology: Toll-like receptors and antibody responses. Nature 441:E4; discussion E4.
6. Hoebe K, Janssen E, Beutler B (2004) The interface between innate and adaptive immunity. Nat Immunol 5:971-974.
7. Boland G, et al. (2004) Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04. Vaccine 23:316-320.
8. Klinman DM (2004) Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 4:249-258.
9. Pulendran B, Ahmed R (2006) Translating innate immunity into immunological memory: Implications for vaccine development. Cell 124:849-863.
10. Hem SL, Hogenesch H (2007) Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Exp Rev Vaccines 6:685-698.
11. Morefield GL, et al. (2005) Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 23:1588-1595.
12. Goto N, et al. (1997) Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminium hydroxide with different physical properties. Vaccine 15:1364-1371.
13. Goto N, Akama K (1982) Histopathological studies of reactions in mice injected with aluminum-adsorbed tetanus toxoid. Microbiol Immunol 26:1121-1132.
14. Kool M, et al. (2008) Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 205:869-882.
15. Dupuis M, et al. (1998) Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell Immunol 186:18-27.
16. Dupuis M, et al. (2001) Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis. Eur J Immunol 31:2910-2918.
17. O'Hagan DT, et al. (2002) Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen. Vaccine 20:3389-3398.
18. Singh M, et al. (2006) A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. Vaccine 24:1680-1686.
19. Vajdy M, et al. (2006) Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses. J Gen Virol 87:2253-2262.
20. Wack A, et al. (2008) Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 26:552-561.
21. Bresson JL, et al. (2006) Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367:1657-1664.
22. Leroux-Roels I, et al.(2007) Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370:580-589.
23. Nicholson KG, et al. (2001) Safety and antigenicity of nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A randomised trial of two potential vaccines against H5N1 influenza. Lancet 357:1937-1943.
24. Garlanda C, et al. (2002) Nonredundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature 420:182-186.
25. Wiendl H, Hohlfeld R, Kieseier BC (2005) Immunobiology of muscle: Advances in understanding an immunological microenvironment. Trends Immunol 26:373-380.
26. Ott G, Barchfeld GL, Van Nest G (1995) Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Vaccine 13:1557-1562.
27. O'Hagan DT (2007) MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Exp Rev Vaccines 6:699-710.
28. Saal LH, et al. (2002) BioArray Software Environment (BASE): A platform for comprehensive management and analysis of microarray data. Genome Biol 3:SOFTWARE0003.
29. Saeed AI, et al. (2003) TM4: A free, open-source system for microarray data management and analysis. BioTechniques 34:374-378.